16 August 2021 | Monday | News
Image Source : builtanempire
India's first nasal vaccine, developed by Bharat Biotech in collaboration with the Department of Biotechnology and its PSU, the Biotechnology Industry Research Assistance Council (BIRAC), got regulatory approval for Phase 2/3 trials on Friday.
Giving an update for the same, a statement by the Ministry of Science & Technology statement said, "Bharat Biotech's intranasal vaccine is the first nasal vaccine that has received the regulatory approval for Phase 2/3 trials. This is the first of its kind COVID-19 jab to undergo human clinical trials in India. BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine. BBIL has in-licensed technology from Washington University in St Louis, USA."
The company reported that the phase 1 clinical trials have been completed for the ages of 18 to 60 years. The doses administered to healthy volunteers in the Phase I trial have been well-tolerated and no serious adverse events were reported, the company said.